Formerly a partner at each of Hogan Lovells and Dorsey & Whitney, Peter has more than 25 years’ transactional and advisory experience in capital markets, M&A, venture capital and corporate governance.
Peter’s clients have included a variety of domestic and multinational corporations, financial institutions, investment funds and entrepreneurs. His practice has ranged from emerging growth industries (including financial technology, pharma/biotech and online consumer businesses) to emerging markets (such as Russia, India, China and Eastern Europe).
Peter is qualified in both England and the United States, with degrees from Harvard College (political science) and Georgetown University (law).
Peter is named as a recognised lawyer for M&A and Flotations/Capital Markets work in the 2017 edition of the Legal 500.
Representative M&A experience includes:
Advising on the up to US$200M sale of a US privately held media company MediaLink to a FTSE 250 company, Ascential PLC.
Advising the founding shareholder of UAB Palink, a major grocery retail chain in Lithuania, in the €213M sale of Palink to ICA Gruppen (a leading Swedish grocery business).
Advising Onexim Group (Russian private equity investment company) in the US$16B swap of shares of Norilsk Nickel for shares in United Company Rusal Ltd.
Advising Onexim Group (Russian private equity investment company) in the US$500M acquisition of Renaissance Capital.
Advising Patni Computer Systems (Indian IT company), on its US$800M takeover by a US and Indian tender offer made by iGate Corporation.
Representative Capital Markets experience includes:
Advising SAB Miller in multiple bond offerings totalling in excess of US$80B in proceeds.
Advising Optimal Payments Plc (now Paysafe Group plc) in a £450M rights issue, listed on the London Stock Exchange and sold to US investors in a Rule 144A offering.
Advising Mirland Development Corporation Plc on its US$293M placing and admission to the AIM Market and sold to US investors in a Rule 144A offering.
Advising Numis Securities Limited on the £135M placing undertaken by Clinigen Group Plc and admission to the AIM Market.